Sign in
Explore the registryTrack Tremelimumab's trials

EMERALD-3

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

TremelimumabOngoingActive not recruitingPhase 3Open NCT05301842 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…

EMERALD-3 · Trial Tracker · ComplyRx